CF
ALXN

Cypress Funds’s Alexion Pharmaceuticals ALXN Stock Holding History

Cypress Funds’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-222,000
Closed -$26.9M – 32
2017
Q1 		$26.9M Buy
222,000
+29,000
+15% +$3.74M 5.61% 5
2016
Q4 		$23.6M Buy
193,000
+115,000
+147% +$14.1M 3.98% 7
2016
Q3 		$9.56M Buy
+78,000
New +$10M 2.05% 22

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cypress Funds's ALXN Position: Q2 2017 in Review

Cypress Funds sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 222,000 shares — an estimated $26.9M sold.

Cypress Funds first reported a position in ALXN in Q3 2016 and held it in 3 quarters. The position peaked at $26.9M in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Cypress Funds reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Cypress Funds sold 222,000 Alexion Pharmaceuticals shares in Q2 2017, an estimated $26.9M.
  • Cypress Funds first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Cypress Funds's Alexion Pharmaceuticals position peaked at $26.9M in Q1 2017.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Cypress Funds's 13F filing for Q2 2017, filed 25 Jul 2017.